基于相对风险重新定义局部晚期p16阳性口咽癌的治疗降强度候选人群
这项多机构队列研究纳入444例既往未治疗的p16阳性口咽鳞状细胞癌患者,比较NRG-HN005 favorable风险标准与头颈癌间组预测分类器(omega评分)识别降强度候选人群的效果。中位随访52个月,120例(27.0%)为favorable风险,另120例omega评分低,仅28例(6.3%)同时符合两项标准,184例(41.4%)分类不一致。omega评分降低与接受强化治疗几率降低显著相关,且在接受顺铂和/或铂类诱导治疗的患者中与癌症事件相对风险显著降低相关,模拟显示选择低omega评分患者可提高假设非劣效试验的效率。
要点
- 444例p16阳性口咽癌患者中,favorable风险与低omega评分各120例,仅28例(6.3%)同时符合,184例(41.4%)分类不一致。
- omega评分每降低1个标准差,接受强化治疗的归一化比值比为0.37(95%CI 0.24-0.57)。
- 接受顺铂和/或铂类诱导治疗患者中,favorable风险与无进展生存改善相关(HR 0.59,95%CI 0.36-0.99),低omega评分与癌症事件相对风险显著降低相关(相对风险比0.18,95%CI 0.070-0.46)。
核心结论
- 考虑患者癌症事件的相对风险有助于界定p16阳性口咽鳞状细胞癌治疗降强度的最优人群。
研究设计与样本
- 多机构队列研究,纳入2009年至2022年间接受根治性放疗伴或不伴全身治疗的444例既往未治疗的p16阳性口咽鳞状细胞癌患者。
- 比较两种识别降强度候选人群的方法:基于NRG-HN005入组标准的favorable与unfavorable风险分组,以及基于头颈癌间组预测分类器(omega评分)的低与高癌症事件相对风险分组。
主要发现
- 中位随访52个月,120例(27.0%)为favorable风险,另120例omega评分低,28例(6.3%)同时符合两项标准,184例(41.4%)分类不一致。
- 有序逻辑回归显示,omega评分降低与接受强化治疗的几率显著降低相关(归一化比值比0.37/SD,95%CI 0.24-0.57),效应幅度大于favorable风险组(比值比0.66,95%CI 0.44-0.99)。
- 在接受顺铂和/或铂类诱导治疗的374例患者中,favorable风险与无进展生存显著改善相关(风险比0.59,95%CI 0.36-0.99),低omega评分与癌症事件相对风险显著降低相关(相对风险比0.18,95%CI 0.070-0.46)。
- 模拟显示,选择低omega评分患者可提高假设非劣效试验的效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Randomized trials have found that patients with locoregionally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC) do not benefit from treatment deintensification, even among favorable risk groups. Although various methods have been used to identify candidates for treatment deintensification, the optimal approach is unknown. METHODS AND MATERIALS: We conducted a multi-institutional cohort study of 444 patients with previously untreated p16+ OPSCC undergoing definitive radiation therapy with or without systemic therapy between 2009 and 2022. We compared the following 2 approaches for identifying candidates for deintensification: (1) favorable versus unfavorable risk, using NRG-HN005 eligibility criteria, and (2) low versus high relative risk of cancer events, using the Head and Neck Cancer Intergroup predictive classifier ("omega score"). We tested differences in outcomes and systemic therapy allocation by risk group using multivariable Cox models, competing event models, and logistic regression, and compared characteristics of hypothetical deintensification trials using the 2 approaches. Progression-free survival events were defined as cancer recurrence (locoregional or distant) or death from any cause. RESULTS: Median follow-up time was 52 months; 120 patients (27.0%) were favorable risk; a different 120 patients had low omega score; 28 patients (6.3%) met both criteria; 184 patients (41.4%) had discordant classification. On ordinal logistic regression, decreasing omega score was associated with a statistically significantly lower odds of receiving intensive therapy (normalized odds ratio, 0.37 per SD; 95% CI, 0.24-0.57), with a greater magnitude than favorable risk group (odds ratio, 0.66; 95% CI, 0.44-0.99). Among patients receiving cisplatin and/or platinum-based induction (n = 374), favorable risk was associated with significantly improved progression-free survival (hazard ratio, 0.59; 95% CI, 0.36-0.99), whereas lower omega score was associated with a significantly decreased relative hazard for cancer events (relative hazard ratio, 0.18; 95% CI, 0.070-0.46). In simulations, selecting patients with low omega scores increased the efficiency of hypothetical noninferiority trials. CONCLUSIONS: Considering patients' relative risk of cancer events can help define optimal populations for treatment deintensification in p16+ OPSCC.
引用
- Morse RT, Nelson TJ, Liu HC, et al. Redefining Candidates for Deintensification in Locoregionally Advanced P16+ Oropharyngeal Cancer Based on Relative Risk. Int J Radiat Oncol Biol Phys. 2024. PMID: 39307324. doi:10.1016/j.ijrobp.2024.09.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。